Hybrid Community/VHA Oncology Forums: Improving Patient Outcomes via Antibody-Drug Conjugates in Non-Small Cell Lung Cancer

Hybrid Community/VHA Oncology Forums: Improving Patient Outcomes via Antibody-Drug Conjugates in Non-Small Cell Lung Cancer

Explain the biologic rationale and mechanism of action underlying the efficacy of ADCs targeting HER2, HER3, TROP-2, and c-Met for the treatment of NSCLC Evaluate available efficacy and safety findings of approved and investigational ADCs indicated for the treatment of NSCLC Apply the latest evidence, guidelines, and expert recommendations to make treatment selections for patients with NSCLC, including the optimal placement of ADCs within evolving treatment paradigms Implement multidisciplinary strategies to monitor, proactively identify, and treat adverse events associated with ADCs in the community and VA healthcare settings

  • Provider:Medical Education Resources
  • Activity Link: https://mycme.com
  • Start Date: 2025-01-01 06:00:00
  • End Date: 2025-01-01 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
    Nursing: 1.0 hours
    Pharmacy: 1.0 hours
  • Commercial Support: Source: AstraZeneca (Any division) - Amount: 25000.0 - Is Kind Support: False
  • Activity Type: Live Course
  • CME Finder Type: Conference
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Knowledge, Learner/Team Competence
  • Provider Ship: Jointly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.